INVO Fertility, Inc. announced their second quarter 2025 financial results, highlighting revenue growth and operational achievements.
The company reported a new quarterly revenue record of $1,863,654, with a 1% increase compared to the same period in 2024.
Notable operational highlights include recognition on Newsweek's List of America's Best Fertility Clinics and the launch of telehealth services at the Wisconsin clinic.
Revenue Growth
Revenue increased by 1% to $1,863,654, marking a new quarterly record for the company.
Operational Achievements
Wisconsin Fertility Institute recognized on Newsweek's List of America's Best Fertility Clinics for 2025, showcasing excellence in ART provision.
Innovative Services
Introduction of Platelet-Rich Plasma therapy at the Wisconsin clinic expands treatment options for fertility challenges.
Intellectual Property Protection
Receiving a new patent for a modified INVOcell device design, extending IP protection through 2040.
Strategic Focus
Completion of the divestiture of NAYA Therapeutics to refocus exclusively on fertility operations.
- The financial results show consistent revenue growth and a strong operational focus on expanding services and enhancing patient care.
- Recognition on Newsweek's list further solidifies the company's reputation as a top-notch fertility clinic provider.
- The launch of telehealth services and new treatments like PRP therapy demonstrate a commitment to innovation and patient-centric care.
INVO Fertility's second quarter 2025 results highlight a successful period of growth, innovation, and strategic alignment. The company's commitment to excellence in fertility services and patient care positions it well for future success.